Descrizione Azione

DRVYIHPFH

Codice: E-PP-0676_5mg Confezionamento: 5mg
Dettagli

DRVYIHPFH

Codice: E-PP-0676_10mg Confezionamento: 10mg
Dettagli

DRVYIHPFH

Codice: E-PP-0676_100mg Confezionamento: 100mg
Dettagli

ARVYIHPF

Codice: E-PP-0677_5mg Confezionamento: 5mg
Dettagli

ARVYIHPF

Codice: E-PP-0677_10mg Confezionamento: 10mg
Dettagli

ARVYIHPF

Codice: E-PP-0677_100mg Confezionamento: 100mg
Dettagli

C56H78N16O13

Codice: 5-00678 Confezionamento: 4 x 5mg
Dettagli

C41H62N12O11

Codice: 5-00675 Confezionamento: 4 x 5mg
Dettagli

DRVYIHP

Codice: E-PP-0674_100mg Confezionamento: 100mg
Dettagli

DRVYIHP

Codice: E-PP-0674_10mg Confezionamento: 10mg
Dettagli

DRVYIHP

Codice: E-PP-0674_5mg Confezionamento: 5mg
Dettagli

Angiotensin Converting Enzyme 1(ACE1), also known as angiotensin converting enzyme (ACE), kininase II, and peptidy-carboxylpeptidase, is an important component of the renin-angiotensin system (RAS). In the RAS system, angiotensin is converted into angiotensin II. Angiotensin II can cause strong contractions of vascular smooth muscle, increasing peripheral vascular resistance and thereby leading to elevated blood pressure. Excessively high ACE1 activity can directly result in elevated blood pressure. ACE1 inhibitors can achieve the purpose of lowering blood pressure by inhibiting ACE1 activity. The detection principle of this kit: ACE1 catalyzes the decomposition of the substrate, releasing fluorescent products. After adding the inhibitor, the generation of fluorescent substances will be inhibited, and the effect of the inhibitor is determined based on the degree of inhibition.

Codice: E-BC-D016_48T Confezionamento: 48T
Dettagli